NCT07917364Recruiting
Asprosin and miRNA Expression in Young Women With Metabolic Syndrome
Association Between Serum Asprosin Concentration and Expression of Selected miRNAs With Risk Factors and Components of Metabolic Syndrome in Young Women: Diagnostic Perspectives
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
Metabolic syndrome is a major risk factor for cardiovascular disease and type 2 diabetes, and its prevalence in young adults is increasing. Early identification of individuals at risk may improve prevention strategies. This observational, cross-sectional case-control study investigates the relationship between serum asprosin concentration, the expression of six selected circulating microRNAs, and the components and risk factors of metabolic syndrome in young women aged 18 to 35 years. Two equally sized groups will be compared: women meeting NCEP ATP III criteria for metabolic syndrome and healthy age-matched controls. Participants attend a single study visit during which fasting blood samples, anthropometric and body composition measurements, blood pressure, and validated questionnaires assessing physical activity, diet, sleep quality, perceived stress, and quality of life are collected. The study aims to determine whether asprosin and the selected microRNA profile have diagnostic value as biomarkers of metabolic syndrome in this population.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 110 (estimated)
- First submitted
- 16 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Mar 2027
- Lead sponsor
- University of Applied Sciences in Nowy Targ
- Diseases
- Obesity
- NCT number
- NCT07917364
What you commit to
- Study type: Observational
- Planned participants: 110
- From Nov 2026 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Continuous pharmacotherapy for indications other than diabetes and/or hypertension, including any form of hormonal contraception (oral, transdermal, vaginal, implant, injectable or intrauterine)
Age
- Age outside the range of 18 to 35 years
Other
- Irregular menstrual cycle
- Pregnancy or breastfeeding
- Competitive sports training in any discipline
- Current smoking
- Alcohol abuse
- Lack of written informed consent for study participation and processing of personal data
Who the study is looking for
- Female sex
- Age 18 to 35 years
- Regular menstrual cycle
- Not engaged in competitive sports training in any discipline
- Non-smoker
- No alcohol abuse
- No continuous pharmacotherapy, with the exception of treatment for diabetes and/or antihypertensive treatment; no use of hormonal contraception
- Written informed consent for study participation and processing of personal data
Age in the registry: 18 years to 35 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Medicine, University of Applied Sciences in Nowy Targ, Kokoszków 71, 34-400 Nowy Targ, Poland Coordinator of this site? Confirm its status | Nowy Targ | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.